Allogene Therapeutics, Inc. (ALLO)
NASDAQ: ALLO · IEX Real-Time Price · USD
2.550
+0.110 (4.51%)
At close: Jun 21, 2024, 4:00 PM
2.530
-0.020 (-0.78%)
After-hours: Jun 21, 2024, 7:46 PM EDT

Allogene Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Year
20232022202120202019 2018
Revenue
0.10.16114.0900
Upgrade
Revenue Growth (YoY)
-39.10%-99.86%---
Upgrade
Gross Profit
0.10.16114.0900
Upgrade
Selling, General & Admin
71.6779.3174.1165.2657.47
Upgrade
Research & Development
242.91256.39220.18192.99144.54
Upgrade
Other Operating Expenses
13.250000
Upgrade
Operating Expenses
327.83335.69294.28258.24202.01
Upgrade
Operating Income
-327.74-335.54-180.19-258.24-202.01
Upgrade
Other Expense / Income
-0.474.881.8658.14-17.08
Upgrade
Pretax Income
-327.27-340.41-182.05-316.38-184.93
Upgrade
Income Tax
0000-0.33
Upgrade
Net Income
-327.27-340.41-182.05-316.38-184.59
Upgrade
Shares Outstanding (Basic)
157143136120101
Upgrade
Shares Outstanding (Diluted)
157143136120101
Upgrade
Shares Change
9.63%5.39%12.84%19.11%249.11%
Upgrade
EPS (Basic)
-2.09-2.38-1.34-2.63-1.83
Upgrade
EPS (Diluted)
-2.09-2.38-1.34-2.63-1.83
Upgrade
Free Cash Flow
-239.25-225.71-206.26-181.05-188.14
Upgrade
Free Cash Flow Per Share
-1.52-1.58-1.52-1.50-1.86
Upgrade
Gross Margin
100.00%100.00%100.00%--
Upgrade
Operating Margin
-344986.32%-215087.18%-157.94%--
Upgrade
Profit Margin
-344489.47%-218214.10%-159.57%--
Upgrade
Free Cash Flow Margin
-251841.05%-144685.90%-180.79%--
Upgrade
EBITDA
-313.07-326.12-171.6-308.95-180.5
Upgrade
EBITDA Margin
-329543.16%-209050.64%-150.41%--
Upgrade
Depreciation & Amortization
14.214.310.457.444.42
Upgrade
EBIT
-327.27-340.41-182.05-316.38-184.93
Upgrade
EBIT Margin
-344489.47%-218214.10%-159.57%--
Upgrade
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).